Digipath Inc (DIGP)

[aussiekevin]

There are no customers or clients. They aren't even taking orders of any sort; try to make one and you'll see.

[FourHrWorkwk]

Can a client or customer confirm this rumor?

[Gailm]

They are OUT OF BUSINESS

If you read the fillings the only two licensed employee's quit--cashed out and sold their stock.

DOA.

[doczaius]

Yeah, I thought that was supposed to be a good thing. Price dropping ever since

[FourHrWorkwk]

Nice increase in YOY rev and gross profit. Let’s get some eyeballs!

[pappi]

Financials out. Not totally awful. Market seems to judge the data +.

/p

[FourHrWorkwk]

Market cap is now all most double the other pubco stock play. But still low

[FourHrWorkwk]

I wonder the same. Don’t know why there aren’t more buyers here.

[jaymes11]

why the stock price so low my friend

[FourHrWorkwk]

Digipath Processes Record Number of Samples, Plans Expansion
Samples for Same Period in 2019 Up Fifty Percent
LAS VEGAS, NV, Feb. 04, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Digipath, Inc. (OTCQB: DIGP), is pleased to announce a 50% increase in cannabis sample processing for January of 2020 versus the same period in 2019.  The January total is among the Company’s highest sample processing months in its six-year history.
To meet growing demand, Digipath has purchased a SCIEX Triple Quad 6500+ LC-MS/MS System which is widely considered to be a state-of-the-art diagnostic instrument featuring multi-component IonDrive Technology including the IonDrive High Energy Detector+ that pushes the boundaries of LC-MS/MS quantitation farther than ever before. Additionally, Digipath is in the process of expanding its laboratory space.
“Digipath continues to leverage its pedigree as a trusted and leading cannabis testing laboratory in Nevada,” stated Kyle Remenda, CEO, Digipath Inc. “We are continuing to invest in next-generation technologies to service our growing customer base and expanded sample testing. The Sciex and our larger laboratory should greatly assist us in our expansion and pursuit of greater market share.”
About Digipath, Inc. (OTCQB: DIGP)
Digipath, Inc. supports the cannabis industry’s best practices for reliable testing, data acquisition, formulations, and new canna-tech to the cannabis industry.

[aussiekevin]

Zero content there.

[FourHrWorkwk]

They’re definitely alive-

https://apple.news/A94fNNG10QiCrZU_2RRHLbw

[aussiekevin]

[aussiekevin]

It appears to be out of business.

We've all been had, I am afraid.

[Gailm]

Digipath deal--you are right to worry jaymes11

Yes the PR NEWS LIE (again) was they were building 3 labs at 3 properties controlled by Hemp inc.

Then like everything else nothing--its a long list most have never researched PZOO, FUTL, DEWM actually 19 companies where deals were announced in PR's by HEMP--and then ...dud.

However if you look at Digipath you can see they had mucho problems of their own. Their license was suspended and they were on super best behavior and my guess is--its just a guess-- is FELON BRUCE saw this as a rubber stamp opportunity, and Digipath who is under the regulatory microscope said "I'm outta here"

Of course neither has offered any explanations, and is ALWAYS the case with this company--WHO KNOWS.

Nearly a staggering quarter of a BILLION dollars in accumulated losses, and 5+ who knows BILLION shares drifting around in the ether.

Crap in Crap out.

[jaymes11]

Not looking to good i have a lot of shares todd gone cindy gone no word on new deals

[Gailm]

Anyone know what happened with HEMP INC?

Jan 24 2019 both companies announced a deal to build three on-site labs at alleged Hemp inc operations.

Can anyone provide details as to why nothing has happened?

Trying to get the truth from Hemp inc is a joke.

Thanks.

[FourHrWorkwk]

Thanks!

[europa7]

CANNMED 2019 Safety Panel: The Future of Cannabis Testing

FYI - interesting discussion by panelists on testing...especially input by Dr. Orser...cheers.

Source: posted Oct 2019 by Medicinal Genomics...

https://cannmedevents.com/2019-videos/

https://cannmedevents.com/abstractpresenter-cindy-orser/

Cindy Orser, PhD
Chief Scientific Officer
Digipath, Inc. & DigiPath Labs
PANELIST

https://cannmedevents.com/

Why CannMed?

"CannMed is the leading cannabis science conference, showcasing the greatest minds in cannabis science, medicine, cultivation, and safety. With a booming industry anticipated to exceed $500B by 2028, understanding the complex science and its medical benefits for patients in need is how the CannMed conference series was born. Since the inaugural event at Harvard Medical School in 2016, CannMed has become the platform for the leading minds in cannabis to share their latest findings and unveil breakthrough technologies. Medicinal Genomics invites you Pasadena, September 21-22, for CannMed 2020, so you can experience firsthand why CannMed continues to lead the way in cannabis science conferences."

[europa7]

u r welcome FourHrWorkwk...glt all of us...cheers.

[FourHrWorkwk]

Thank you both.
They will be helped with the new USDA rules

[jaymes11]

yes the have a deal with hemp INC to test hemp at there locations

[europa7]

Digipath's Hemp Potency Testing Laboratories...

https://www.globenewswire.com/news-release/2019/01/24/1705151/0/en/Hemp-Inc-to-Add-Digipath-s-Hemp-Potency-Testing-Laboratories-to-its-3-Main-Hemp-Production-Sites-Across-America-as-Part-of-its-Hemp-Infrastructure-Expansion-Plan.html

interesting...sure would like to get an update soon from Digipath management on status of product testing, marketing, patents, orders, etc...cheers.

"...Currently, Digipath, Inc. (OTCQB: DIGP) through it’s wholly-owned subsidiary Digipath Labs, has been testing cannabis and hemp products since 2015 in the burgeoning Nevada market and will bring state-of-the-art equipment, lab expertise, proprietary operating procedures and management to Hemp, Inc.’s rapidly growing locations. The Company will provide all necessary laboratory-expertise and related management services to develop and operate each Lab, including purchasing and maintenance of the laboratory instrumentation, as well as hiring and comprehensive training of lab personnel.

Todd Denkin, CEO of Digipath, Inc. (OTCQB: DIGP) said, “This opportunity to align with Hemp, Inc. allows us to expand our footprint within their sophisticated hemp business locations. We are thrilled to provide our expertise to support small family farms and be on the forefront of the hemp revolution that is sweeping America.”

“As fast as this industry is growing, having a third-party testing laboratory on-site is what is going to keep us ahead of the curve and will position us as an active hemp business hub and a trusted company in the industry. You have to be compliant and you have to be able to turn products around quickly in this industry. Adding an on-site testing lab will ensure we do both,” said Perlowin.

Without an in-house, third-party testing laboratory, products in need of testing would need to be transported off site, which could mean waiting days or even weeks for results. The addition of Digipath Labs at Hemp, Inc.’s production centers will expedite testing processes and further support new business developments..."

[FourHrWorkwk]

Is digp testing hemp?

https://www.usda.gov/media/press-releases/2019/10/29/usda-establishes-domestic-hemp-production-program

[jaymes11]

DIGP why is there not much going on with this stock ?

[jaymes11]

Good to see I hope pps share starts to move up

[FourHrWorkwk]

Great to see some movement here.

[jaymes11]

yes I feel Todd Denkin did as much as he could the change was good step forward.

[europa7]

yep ~ hence the change in management and company focus apparently. Dr. Orser listed as Science Advisor to VSSL...looks like she has been working closely with their team...the new CEO from VSSL appears to be a go-getter in the marketing and revenue arena...obviously needed by Digipath in a big way...imo...fingers crossed that they can pull this together and get some products to market...cheers.

[jaymes11]

good news for the company. there has not been much upward movement for the stock in a few years

[europa7]

looks like the new DIGP CEO and Director are in place, which is good news. found some background info that might be of interest:

RBC Hemp LLC
http://rbchemp.com/management/
(Kyle Remenda bio listed on this company page...very interesting)

Mergers & Acquisitions
https://aol.theonlineinvestor.com/slideshows/?slideshow=mergers&page=44

Classification of Cannabis Chemovars Using Targeted Single Nucleotide Polymorphism Assays Philippe Henry , PH.D./CSO VSSL

The genetic basis of the human-cannabis relationship
https://www.biorxiv.org/content/biorxiv/early/2018/03/27/287938.full.pdf

Predicting chemovar cluster and variety verification invegetative cannabis accessions using targeted singlenucleotide polymorphisms
https://peerj.com/preprints/27442.pdf

Integrative Cannabis Medicine: the science of making cannabis work better for you
https://www.eventbrite.ca/e/integrative-cannabis-medicine-the-science-of-making-cannabis-work-better-for-you-tickets-58287691053#

Join us for a discussion on Medical Cannabis with
Dr Chris Spooner ND and
Dr Philippe Henry, PhD Biology
Tim Dyer, Registered Pharmacist

Philippe Henry, PhD, is the founder and Chief Science Officer with VSSL Enterprises LTd. He is a population geneticist who uses genomic data to advance the understanding of the genetic basis of key traits of the cannabis plant and its therapeutic potential. Dr. Henry’s recent work has focused on the development of statistical approaches to modeling the chemotypic variation in elite cannabis cultivars and correlating that information with genomic data with the goal of using sound science to objectively guide cannabis breeding efforts and product development. Along with numerous published papers in scientific journals, Dr. Henry is the co-author of a recent preprint article, “Predicting chemovar cluster and variety verification in vegetative cannabis accessions using targeted single nucleotide polymorphisms” (https://peerj.com/preprints/27442/).

His talk will focus on the interface between cannabis chemotypes and the underlying basis of people’s responses to cannabis as a therapeutic agent and recreational substance

Leysin Scientific
http://web.unbc.ca/~henryp/Leysin_scientific.html

[jaymes11]

yikes good news but still hits 52 week lows what do you think

[europa7]

How Finding the Right Cannabis Strains Can Help Find the Right Pot Stocks
https://potstocknews.com/cannabis-strains-guide/

very interesting...

What Does This New Discovery Mean for LPs?

"...At present in Canada, licensed producers are required to provide the cannabinoid potency for all of their cannabis products. The cannabis strains’ terpene profiles, however, are not required and cannot be communicated on the packaging.

In the US, it is much the same; cannabinoid and potency testing are required by state law in legal markets, but testing of terpenes is not. What’s more, it costs growers extra money to conduct terpene testing.

Leafly hopes that its new Cannabis Guide will encourage both growers and consumers to take more interest in terpene data.

Although it remains to be seen how this new set of guidelines for cannabis strains may affect licensed producers, it could lead to increased demand from consumers for more detailed information moving forward. Increased demand for terpene data could, in turn, boost cannabis stocks that offer lab testing.

One company that offers cannabis lab testing services, including terpenoid profiles, is Las Vegas-based Digipath Inc. (OTCQB:DIGP). Digipath was named one of the top 10 cannabis testing companies earlier this year, alongside industry giants Agilent Technologies, Inc. (NYSE:A), PerkinElmer, Inc. (NYSE:PKI), and German-based Merck KGaA (OTCPK:MKGAF).

The Cannabis Testing Market is expected to grow significantly in the coming years to reach $2.4 billion by 2025..."

[jaymes11]

true Canada is a great place to increase revenue

[europa7]

glad to see DIGP expand into Canada...a lot of relevant market activity going on with our cousins to the north

[europa7]

hopes with new CEO and VSSL CSO who have been working closely with DIGP CSO Dr. Orser apparently...looking forward to patent and product announcements...cheers

[jaymes11]

my only concern is they have taken on a lot of debt the positive side is they paid for new company with shares. Todd had to go there have been so many things that have not happened the lab in California it has been 2 years and nothing so there could be a great upside if new ceo makes things happen good luck go DIGP $$$$

[europa7]

hopefully the new management from Canada is successful at marketing the company...toppling the competition...communicating with investors...improving the website quality/function...getting new products developed/tested/packaged/delivered...patents secured...the international business (Columbia, Europe, Canada and hopefully others) off the ground...and significant revenues coming in...etc.

[jaymes11]

all this good news and pps stays the same

[marvin01]

Can someone help me? Why is increasing debt more reasonable than splitting the stock? I thought a 1 for 3 split would accomplish the same thing as increasing the number of shares?

[jaymes11]

your welcome more news should come soon

[europa7]

background info re new DIGP CEO...

Kyle Remenda

https://twitter.com/kyle_remenda?lang=en
http://rbchemp.com/management/

and the Chief Science Officer of VSSL:

Philippe Henry, PhD

https://twitter.com/phdilly
https://peerj.com/preprints/3307/
https://www.researchgate.net/profile/Philippe_Henry

Digipath's Chief Science Officer Explains Company's New Field Test
https://www.prnewswire.com/news-releases/in-case-you-missed-it-digipaths-chief-science-officer-explains-companys-new-field-test-300833634.html

"...Dr. Orser, PhD and Dr. Philippe Henry, PhD are the driving forces behind the development of the field test which has been created to provide relief and clarity for an array of uses where the type of cannabis product must be quickly and accurately determined using a portable methodology. GroSciences, Inc., Digipath's wholly owned subsidiary is seeking a provisional patent for the field test and will be packaging and validating over the next several weeks..."

[europa7]

interesting news. thanks for post jaymes.

[jaymes11]

Digipath to Acquire Cannabis Technology Firm VSSL Enterprises Ltd.

9:30 am ET September 30, 2019 (Globe Newswire) Print


VSSL CEO Kyle Remenda Appointed Digipath Chief Executive Officer

via NEWMEDIAWIRE - Digipath, Inc. (OTCQB: DIGP), is pleased to announce it has entered into a binding letter of intent for the acquisition of VSSL Enterprises Ltd. ("VSSL"), a British Columbia based cannabis genomics, plant sciences and consulting firm. The acquisition is expected to provide Digipath with a wealth of cannabis data, technology and intellectual property, including in excess of a thousand hemp and cannabis genotypes. The letter of intent provides for the acquisition of 100% of VSSL's outstanding shares of capital stock for consideration consisting of six million shares of Digipath common stock and a cash payment of $200,000, and is subject to the execution of definitive agreements.

VSSL builds predictive tools for the cannabis industry. Whether it's for a breeder, cultivator or processor, understanding the genetic basis of key traits such as yield, expression of secondary metabolites or disease resistance can provide a competitive advantage to its clients by allowing rapid decision making and process optimization. VSSL uses molecular and bioinformatics tools to deliver unique solutions suited to its customers' diverse germplasm and business models.

Effective upon signing the letter of intent, VSSL Chief Executive Officer, Kyle Remenda was appointed to serve as Digipath's Chief Executive officer. Todd Denkin, the former CEO, has resigned his positions with Digipath to pursue other opportunities. Under Mr. Denkin's leadership, Digipath has become the leading cannabis testing laboratory in Las Vegas, a leader in data analysis and a recognized brand around the country. He will continue to consult with the Company through the end of 2019.

Mr. Remenda is a passionate advocate within the medical marijuana industry. Under Kyle's leadership, VSSL has become a trusted source of technology and genotype technology and consulting. Before starting VSSL, Mr. Remenda worked in the medical marijuana industry with established legal grow operations in North America. He and the VSSL team bring a wealth of expertise in plant breeding, genetics and production craft.

"Kyle is the right person to lead the next phase in the evolution of Digipath, building on our outstanding pedigree in cannabis technology, vision and experience. With Kyle on board and combining with VSSL, Digipath can move into larger revenue opportunities," stated Todd Denkin.

[jaymes11]

its been so quiet digp seems to have a lot of plans with patterns and growth also testing across the board has to be regulated and standardized I hope the FDA gets involved this will play in digp favor and also taking weed of the schedule 1 drug list it would be huge

[europa7]

what do you make of this jaymes? product announcements incoming perhaps...? fingers crossed...

[jaymes11]

no volume today is this the calm before the storm $$$$

[jaymes11]

Europa 7 you still I hope all testing becomes fda standardized

[jaymes11]

will we ever get back to 0.40

[jaymes11]

Waiting hold strong still